25,210 Shares in Boston Scientific Corporation $BSX Bought by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,210 shares of the medical equipment provider’s stock, valued at approximately $1,100,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the second quarter worth $2,156,233,000. Jupiter Topco LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $803,357,000. Bank of America Corp DE acquired a new stake in shares of Boston Scientific during the second quarter worth $556,026,000. Finally, Legal & General Group Plc acquired a new stake in shares of Boston Scientific during the second quarter worth $431,890,000. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. The Goldman Sachs Group reduced their price objective on Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Needham & Company LLC cut their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Piper Sandler reduced their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $80.00 to $56.00 and set an “overweight” rating for the company in a research report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $68.23.

Insider Buying and Selling

In other news, Director David Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward Ludwig bought 5,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 194,522 shares of company stock valued at $9,385,210 over the last quarter. 0.34% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $0.34 during mid-day trading on Friday, reaching $45.67. 8,771,849 shares of the company were exchanged, compared to its average volume of 15,836,739. The company’s 50-day simple moving average is $45.46 and its 200-day simple moving average is $49.16. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.11 and a beta of 0.58. Boston Scientific Corporation has a twelve month low of $41.38 and a twelve month high of $105.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the company posted $0.75 earnings per share. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.